Facility is now available to manufacture study drug, MT-401, for Marker's Phase 2 AML trial
PR Newswire
HOUSTON, July 28, 2021
PR Newswire
HOUSTON, July 28, 2021
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey